Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H17FN5O13P3 |
| Molecular Weight | 539.1981 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]1(F)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N2C=NC3=C2N=C(N)NC3=O
InChI
InChIKey=GFEXCNGIPRYQFE-GITKWUPZSA-N
InChI=1S/C11H17FN5O13P3/c1-11(12)6(18)4(2-27-32(23,24)30-33(25,26)29-31(20,21)22)28-9(11)17-3-14-5-7(17)15-10(13)16-8(5)19/h3-4,6,9,18H,2H2,1H3,(H,23,24)(H,25,26)(H2,20,21,22)(H3,13,15,16,19)/t4-,6-,9-,11-/m1/s1
PSI-352938 is a nucleoside derivative patented by Pharmasset, Inc. as an antiviral agent. PSI-352938 acts as a novel cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine-5'-monophosphate with potent anti-HCV activity. PSI-352938 inhibits HCV genotype (GT) 1b replicon replication with 50% effective concentrations (EC50s) of 0.13 ± 0.076 μM, and active against GT 1a and 2a replicons and infectious viruses PSI-352938 retained full activity against replicons containing the S282T substitution, which confers resistance to certain 2'-substituted nucleoside/nucleotide analogs. In April 2013, because of hepatic toxicity, Gilead Sciences discontinued the development of PSI-352938.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. | 2011-12 |
|
| Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine. | 2011-06 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
136141536
Created by
admin on Wed Apr 02 00:11:11 GMT 2025 , Edited by admin on Wed Apr 02 00:11:11 GMT 2025
|
PRIMARY | |||
|
IR49Q7E87C
Created by
admin on Wed Apr 02 00:11:11 GMT 2025 , Edited by admin on Wed Apr 02 00:11:11 GMT 2025
|
PRIMARY | |||
|
1261253-79-5
Created by
admin on Wed Apr 02 00:11:11 GMT 2025 , Edited by admin on Wed Apr 02 00:11:11 GMT 2025
|
PRIMARY |
PARENT (METABOLITE ACTIVE)
